| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/22/2013 | US8357783 Human anti-mesothelin monoclonal antibodies |
| 01/22/2013 | US8357782 Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
| 01/22/2013 | US8357781 Neuroactive fragments of APP |
| 01/22/2013 | US8357780 Polypeptides, antibody variable domains and antagonists methods for |
| 01/22/2013 | US8357774 Polypeptide and process for producing the same |
| 01/22/2013 | US8357494 Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits |
| 01/22/2013 | US8357424 Preparation of nanoparticle chains comprising reacting of functional groups |
| 01/22/2013 | US8357371 Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| 01/22/2013 | US8357370 Anti-D monoclonal antibodies |
| 01/22/2013 | US8357368 Methods of treating pancreatic or liver cancer using hedgehog antagonists |
| 01/22/2013 | US8357367 Antibodies that bind PAR-2 |
| 01/22/2013 | CA2692552C Novel protein isolated from pleurotus cornucopiae |
| 01/22/2013 | CA2489515C Methods and compositions for modulating and detecting wisp activity |
| 01/22/2013 | CA2483819C Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus |
| 01/22/2013 | CA2425862C Cd19-specific redirected immune cells |
| 01/22/2013 | CA2375619C Equine granulocyte-macrophage colony-stimulating factor (gm-csf) |
| 01/22/2013 | CA2329267C A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upflp, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 01/17/2013 | WO2013009967A2 Identifying affinity-matured human antibodies |
| 01/17/2013 | WO2013009843A1 Compositions against bacterial toxins |
| 01/17/2013 | WO2013009793A1 Chymase compositions, antibodies, diagnostics, and therapeutic methods related thereto |
| 01/17/2013 | WO2013009526A1 Method for purifying fc-fusion protein |
| 01/17/2013 | WO2013008743A1 Chlamydophila pneumoniae antigen and usage thereof |
| 01/17/2013 | WO2013008185A1 Treatment with anti-pcsk9 antibodies |
| 01/17/2013 | WO2013008171A1 Antibodies that bind to ox40 and their uses |
| 01/17/2013 | WO2013008100A1 Methods for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013008099A1 Antibodies for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013008098A1 Antibodies for the treatment and prevention of thrombosis |
| 01/17/2013 | WO2013007839A1 Antibodies to phosphorylated tau aggregates |
| 01/17/2013 | WO2013007801A1 Predictive tool for response to anti-igf-1r antibody therapy in cancer patients |
| 01/17/2013 | WO2013007770A1 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| 01/17/2013 | WO2013007763A1 MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
| 01/17/2013 | WO2013007740A1 Method for preparing a polyvalent-immunoglobulin concentrate |
| 01/17/2013 | WO2013007678A1 Use of antagonists targeting metallothionein to treat intestinal inflammation |
| 01/17/2013 | WO2013007667A1 An antibody specifically binding to neuropilin-1 |
| 01/17/2013 | WO2013007643A1 In vitro assessment of cardiovascular events by assay for neo-epitopes of titin protein |
| 01/17/2013 | WO2013007388A1 Bacterial host strain expressing recombinant dsbc |
| 01/17/2013 | WO2013007053A1 Fully human antibodies against human vegf |
| 01/17/2013 | WO2013007052A1 Fully human antibodies against human cd20 |
| 01/17/2013 | WO2013006972A1 Novel anti-cancer isocarbostyril alkaloid conjugates |
| 01/17/2013 | WO2012162243A3 Anti-cgrp compositions and use thereof |
| 01/17/2013 | WO2012162165A3 Antibodies to 25-hydroxyvitamin d2 and d3 and uses thereof |
| 01/17/2013 | WO2012158989A3 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| 01/17/2013 | WO2012144784A3 Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof |
| 01/17/2013 | WO2012143382A3 Gpr177 as target and marker in tumors |
| 01/17/2013 | WO2012121775A9 Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| 01/17/2013 | WO2012061558A3 Dual variable domain immunoglobulins and uses thereof |
| 01/17/2013 | US20130019342 Polynucleotides encoding trehalose-6-phosphate phosphatase and methods of use thereof |
| 01/17/2013 | US20130019326 Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Metabolic Disorders |
| 01/17/2013 | US20130018176 Methods of producing hybridomas and monoclonal antibodies and antibodies produced thereby |
| 01/17/2013 | US20130018175 Single variable domain antibodies against ox40l, constructs and therapeutic use |
| 01/17/2013 | US20130018174 Polypeptide modification method for purifying polypeptide multimers |
| 01/17/2013 | US20130018173 Identifying Affinity-Matured Human Antibodies |
| 01/17/2013 | US20130018087 miRNA Compounds for Treatment of Prostate Carcinoma |
| 01/17/2013 | US20130017965 Osteoarthritis biomarkers and uses thereof |
| 01/17/2013 | US20130017561 Lateral Flow Device for Diagnosing Microbial Infections |
| 01/17/2013 | US20130017558 Adam12 as a biomarker for bladder cancer |
| 01/17/2013 | US20130017546 Breast Tumor Markers and Methods of Use Thereof |
| 01/17/2013 | US20130017266 Radiation Therapy Agent |
| 01/17/2013 | US20130017251 Antibody Specific for Apolipoprotein and Methods of Use Thereof |
| 01/17/2013 | US20130017214 Bacteremia-associated antigen from staphylococcus aureus |
| 01/17/2013 | US20130017208 Anti-IL-6 Antibodies, Compositions, Methods and Uses |
| 01/17/2013 | US20130017205 Inhibition of AXL Signaling in Anti-Metastatic Therapy |
| 01/17/2013 | US20130017204 Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae |
| 01/17/2013 | US20130017202 Pharmaceutical compositions and methods of treatment |
| 01/17/2013 | US20130017201 Bispecific monoclonal antibody capable of cross reacting with lethal factor (lf) and edema factor (ef), and neutralizing edema toxin (et) as well as lethal toxin (lt) of bacillus anthracis |
| 01/17/2013 | US20130017200 Multispecific antibodies, antibody analogs, compositions, and methods |
| 01/17/2013 | US20130017198 Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes |
| 01/17/2013 | US20130017195 Anti-folate receptor alpha antibodies and uses thereof |
| 01/17/2013 | US20130017169 Multimeric forms of therapeutic proteins and uses thereof |
| 01/17/2013 | CA2857369A1 Fully human antibodies against human cd20 |
| 01/17/2013 | CA2841864A1 Novel anti-cancer isocarbostyril alkaloid conjugates |
| 01/17/2013 | CA2841824A1 Bacterial host strain expressing recombinant dsbc |
| 01/17/2013 | CA2841475A1 Identifying affinity-matured human antibodies |
| 01/17/2013 | CA2840951A1 Method for purifying fc-fusion protein |
| 01/17/2013 | CA2840482A1 Treatment with anti-pcsk9 antibodies |
| 01/17/2013 | CA2840460A1 Antibodies that bind to ox40 and their uses |
| 01/17/2013 | CA2840282A1 Use of antagonists targeting metallothionein to treat intestinal inflammation |
| 01/17/2013 | CA2838999A1 Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| 01/17/2013 | CA2838930A1 Method for preparing a polyvalent-immunoglobulin concentrate |
| 01/16/2013 | EP2546347A2 Glycoprotein composition from engineered galactose assimilation pathway in Pichia pastoris |
| 01/16/2013 | EP2546342A1 Method for selecting polypeptide sequence, metal oxide or silicon containing compound binding peptide and use thereof |
| 01/16/2013 | EP2546269A1 Monoclonal antibody against necrosis marker prdx4 and use thereof |
| 01/16/2013 | EP2546268A1 Internalising immunoglobulin |
| 01/16/2013 | EP2546267A1 Bacterial host strain expressing recombinant DsbC |
| 01/16/2013 | EP2546266A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |
| 01/16/2013 | EP2546265A1 Eukaryotic cell-free protein expression system especially suitable for disulfide-bridges comprising proteins |
| 01/16/2013 | EP2545938A1 Therapeutic use of anti-tweak receptor antibodies |
| 01/16/2013 | EP2545936A2 Methods, compositions, and kits for treating Shiga toxin associated conditions |
| 01/16/2013 | EP2545383A1 Specific detection of human chorionic gonadotropin beta subunit type ii produced by trophoblastic and neoplastic cells |
| 01/16/2013 | EP2545376A2 Methods of predicting and decreasing the risk of pregnancy loss |
| 01/16/2013 | EP2545171A1 Hjurp peptides and vaccines including the same |
| 01/16/2013 | EP2545081A1 Free hexasaccharide isolated from several campylobacter species |
| 01/16/2013 | EP2545079A2 ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| 01/16/2013 | EP2545078A1 Pd-1 antibody |
| 01/16/2013 | EP2545077A2 Monoclonal antibodies against c-met |
| 01/16/2013 | EP2545076A1 Biological products: humanised agonistic anti-pd-1 antibodies |
| 01/16/2013 | EP2545075A2 Humanized and chimeric anti-properdin antibodies |
| 01/16/2013 | EP2545074A2 Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| 01/16/2013 | EP2545066A1 Method for purifying immunoglobulin solutions |
| 01/16/2013 | EP2544785A1 Immunoglobulin g fc region binding polypeptide |